Results 251 to 260 of about 17,826,638 (304)

Acute and Chronic Leukemia in Sub-Saharan Africa: A Systematic Review. [PDF]

Cancer Rep (Hoboken)
Ayirebi AA, Twumasi S, Olaga LK, Sackey B, Antonio DNM, Ansah RO, Ansah EA, Sah JA, Anto EO, Anang-Quartey Y, Koomson A, Opoku A, Donkor GA, Duah P, Boadu AG, Essien-Baidoo S, Boadu WIO, Boateng LA.   +17 more
europepmc   +1 more source

The Unusual Coexistence of Chronic Lymphocytic Leukemia, Dengue Fever, and Acute Kidney Injury: A Case Report. [PDF]

Clin Case Rep
Khan M, Bibi S, Khan Z, F N U Ruqayya, Chaudhry A, Khan N, Khan A, Kamil KA, Zainullah FNU.   +8 more
europepmc   +1 more source

Treatment of advanced cutaneous squamous cell carcinoma with cemiplimab in elderly multimorbid patients – a case series

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Patryk Porebski, Katharina Amschler, Michael P. Schön, Kai‐Martin Thoms   +3 more
wiley   +1 more source

Renal Involvement in Indolent and Aggressive B-Cell Neoplasms: A Comparative Study of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Diffuse Large B-Cell Lymphoma. [PDF]

Curr Oncol
Zhao Y, Wang B, Liu H, Yang X, Lai Z, Tang B, Xie W, Ling H, Xie S, Guo S, Yu X, Dong Y.   +11 more
europepmc   +1 more source

Real-World Diagnostic Yield and Longitudinal Dynamics of Fluorescence In Situ Hybridization in Hematologic Malignancies: A Five-Year Retrospective Analysis of 1357 Patient Samples. [PDF]

Genes (Basel)
Fumo R, Scala K, Gaeta S, D'Ardia A, Infante T, Ciancia G, Caputo A, Rosati A, Serio B, D'Antonio A, Zeppa P, Chetta M.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The Origin of B-Cell Chronic Lymphocytic Leukemia

Seminars in Oncology, 2006
An immunobiologic approach has led to substantial changes in our current view of chronic lymphocytic leukemia (CLL). Several questions remain unsolved and the definition of the cell origin of CLL is still prominent. The presence of somatic mutations of IGHV genes indicates that, at least in a portion of cases, CLL cells had encountered an antigen ...
GHIA , PAOLO PROSPERO, Caligaris Cappio F.   +1 more
openaire   +2 more sources

Cytokines in B-Cell Chronic Lymphocytic Leukemia

Leukemia & Lymphoma, 1991
The pleomorphic action of different cytokines in regulating the growth and proliferation of normal B- and T-lymphocyte populations is becoming progressively more apparent. Thus, the possibility that some cytokines, either alone or in variable combination, may play a role in different lymphoproliferative disorders has been increasingly suggested and ...
FOA, Roberto, Gillio Tos A., Francia di Celle P., Carbone A., Marchis D., Vischia F., Cignetti A., GUARINI, Anna   +7 more
openaire   +3 more sources

Histopathology of B-cell chronic lymphocytic leukemia

Hematology/Oncology Clinics of North America, 2004
Histologic and immunohistologic findings of B-cell chronic lymphocytic leukemia/small lymphocytic leukemia are revised in the light of the more recent knowledge on the pathobiology of the disease. The guidelines for the optimal handling of the bioptic samples are provided. The relevance of the examination of trephines and surgical specimens is outlined
PILERI, STEFANO, SABATTINI, ELENA, AGOSTINELLI, CLAUDIO, BODEGA L, ROSSI M, ZINZANI, PIER LUIGI, MARAFIOTI, TERESA   +6 more
openaire   +2 more sources

Alemtuzumab in B-Cell Chronic Lymphocytic Leukemia

Clinical Lymphoma, 2004
Chronic lymphocytic leukemia (CLL) is the most frequent form of leukemia in the Western hemisphere.1 In this disease, a clonal proliferation of neoplastic B lymphocytes accumulates in bone marrow, blood, lymph nodes, liver, and spleen. According to the World Health Organization (WHO) classification, B-cell CLL is a mature (peripheral) B-cell neoplasm ...
Ilan, Shapira, Michael L, Grossbard
openaire   +2 more sources

Rituximab in B-Cell chronic lymphocytic leukemia

Seminars in Oncology, 2003
The monoclonal anti-CD20 antibody rituximab exerts its antitumor activity through a variety of mechanisms, including acting against the cellular defects in apoptosis that give rise to B-chronic lymphocytic leukemia (B-CLL). Phase II clinical studies demonstrated that rituximab, given weekly as a single agent, exhibits significantly less activity in B ...
Thomas S, Lin, Margaret S, Lucas, John C, Byrd   +2 more
openaire   +2 more sources